New cocktail of four drugs aims to tackle childhood cancers that Won't go away

NCT ID NCT05468359

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can shrink tumors. The trial has two parts: the first focuses on safety and dosing, and the second looks at how well the treatment works in specific rare cancers like fibrolamellar carcinoma and hepatocellular carcinoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab, sorafenib, bevacizumab, and cyclophosphamide
What this could lead to
If successful, this could offer a new treatment option for children with relapsed or hard-to-treat solid tumors, including rare liver cancers.
What could go wrong
This is an early-phase trial with a small number of participants. The drug combination may cause serious side effects, and it is not yet known if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOPLASTIC SMALL ROUND CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Methodist Le Bonheur Healthcare

    WITHDRAWN

    Germantown, Tennessee, 38138, United States

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.